
BioTheryX Stock
BioTheryX is a clinical-stage biopharmaceutical company that focuses on the development of therapies for hematological malignancies.
Sign up today and learn more about BioTheryX Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About BioTheryX Stock
BioTheryX focuses on the development of therapies for hematological malignancies. It intends to leverage its extensive experience and proven commercial success to deliver efficacious therapies to patients with unmet medical needs more quickly and less expensively than the biomedical industry traditionally can and does. To do so, they are exploiting enhanced biology-driven models to identify effective core molecules that can be rapidly exploited using focused and prioritized chemistry approaches coupled with clinically proven translational approaches targeted for cancer and immune dysfunction. The company was founded in 2007 and is headquartered in Chappaqua, New York.
Funding History
2014-06-01 | $1.0M |
---|---|
2014-09-01 | $150K |
2015-05-01 | $500K |
2020-07-01 | $35.0M |
2021-05-01 | $18.0M |
2021-05-01 | $92.0M |
Management
Chief Business Officer
Sahm Nasseri
Chief Financial Officer
Jeff Caravella
Co-Founder, President & Board Member
Lawrence Zaslow
Co-Founder, Chief Development Officer & Chairman & Owner
David Stirling
Board Member
Robert Platek
Chief Executive Officer
Philippe Drouet
Press
bioworld - Apr, 8 2023
Biotheryx and Incyte collaborate on targeted protein degraders for novel oncology targetsendpts - Apr, 7 2023
Incyte links arms with tiny Biotheryx for protein degrader deal, targeting cancerprnewswire - Aug, 24 2022
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officerprnewswire - Apr, 25 2022
Biotheryx Announces Appointment of Jeff Caravella as Chief Financial Officerbiospace - Feb, 24 2022
BioTheryX Appoints Nancy Miller-Rich as Chair of Its Board of Directorssocaltech - Jan, 20 2022
BioTheryX Names Chief Business Officerprnewswire - Jan, 20 2022
BioTheryX Announces Appointment of Sahm Nasseri as Chief Business Officerprnewswire - Oct, 28 2021
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officersdbj - Jun, 14 2021
BioTheryX Raises $92M in Series E Roundfiercebiotech - May, 22 2021
Left out of SPAC pack, BioTheryX raises $92M in rare series E to hold over until potential end of year IPOtinyurl - May, 21 2021
BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC playertinyurl - May, 21 2021
BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncologyblog - May, 20 2021
BioTheryX Gets $92Mnews - Sep, 22 2020
BioTheryX to Participate at Upcoming Industry Conferencesvcaonline - Jul, 30 2020
Venture Capital Database 2020 Now Available!sdbn - Jul, 29 2020
BioTheryX Announces $35 Million Series D FinancingEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase